University of California, Los Angeles (US)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
159
Publications
1735
Citations
165320
i10-index
540
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Improved Survival with Vemurafenib in Melanoma wit... | 2011 | 7743 |
Cancer immunotherapy using checkpoint blockade | 2018 | 6731 |
PD-1 blockade induces responses by inhibiting adap... | 2014 | 6604 |
Pembrolizumab versus Ipilimumab in Advanced Melano... | 2015 | 5889 |
Primary, Adaptive, and Acquired Resistance to Canc... | 2017 | 5545 |
Genetic Basis for Clinical Response to CTLA-4 Bloc... | 2014 | 4296 |
IFN-γ–related mRNA profile predicts clinical respo... | 2017 | 3767 |
Inhibition of Mutated, Activated BRAF in Metastati... | 2010 | 3571 |
Genomic and Transcriptomic Features of Response to... | 2016 | 3445 |
Safety and Tumor Responses with Lambrolizumab (Ant... | 2013 | 3399 |
Antoni Ribas is a researcher with 1735 publications and 165320 citations. They are affiliated with University of California, Los Angeles. Their research focuses on . With an h-index of 159, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Antoni Ribas and 250M+ other papers.
Citations per publication by year